^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | elimusertib (BAY 1895344) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ELIMUSERTIB, AN ORAL ATAXIA TELANGIECTASIA AND RAD3-RELATED INHIBITOR, IN ADVANCED GYNECOLOGIC CANCERS WITH DNA DAMAGE RESPONSE DEFECTS
Published date:
09/08/2022
Excerpt:
Overall response rate was 2% (1/44 evaluable); 77% of patients had a best response of stable disease. In ovarian cancer patients, the clinical benefit rate at 120 days was 40%, including patients with previous PARPi treatment; 19% of patients had ≥50% reduction in CA-125 levels....Elimusertib demonstrated clinical benefit in heavily pretreated gynecologic cancers with DDR defects.
Trial ID:
